Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

18 Jun 2026, 10:45 UTC · 2h ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

What the story claims

1 claim · each scored for market impact

What matters in this story

1
The U.S. FDA has approved an additional indication for Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). — Expanded indications typically increase the addressable patient population and potential revenue streams for the drug.
+0.40

Which stocks this story touches

How each ticker is affected

MRK+0.80
The FDA approved an additional indication for the company's CAPVAXIVE vaccine.

Read original · https://www.businesswire.com/news/home/20260618416609/en/U.S.-FDA-Approves-an-Additional-Indication-for-CAPVAXIVE%C2%AE-Pneumococcal-21-valent-Conjugate-Vaccine-in-Children-and-Adolescents-Aged-2-through-17-at-Increased-Risk-for-Pneumococcal-Disease/

6 related stories

Reuters
2h ago
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
- fda approval
- healthcare
- pharma
Read

U.S. FDA Approves an Addit… — MRK +0.80 | NewsImpactScreener

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

What matters in this story

How each ticker is affected

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

What matters in this story

How each ticker is affected

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

Grey Matters Health raises C$1.25M to fund US neuroimaging clinic for Alzheimer's program

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?

Pfizer Announces Chief Financial Officer Transition

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

What matters in this story

How each ticker is affected

Next reads from the same story arc

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

What matters in this story

How each ticker is affected

Next reads from the same story arc

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

Grey Matters Health raises C$1.25M to fund US neuroimaging clinic for Alzheimer's program

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?

Pfizer Announces Chief Financial Officer Transition